The recent studies have revealed that most BRAF inhibitors can paradoxically induce kinase activation by promoting dimerization and enzyme transactivation. Despite rapidly growing number of structural and functional studies about the BRAF dimer complexes, the molecular basis of paradoxical activation phenomenon is poorly understood and remains largely hypothetical. In this work, we have explored the relationships between inhibitor binding, protein dynamics and allosteric signaling in the BRAF dimers using a network-centric approach. Using this theoretical framework, we have combined molecular dynamics simulations with coevolutionary analysis and modeling of the residue interaction networks to determine molecular determinants of paradoxical ...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
An autoinhibitory network of hydrogen bonds located at the kinase hinge (referred to as the "molecul...
BRAF<sup>V600E</sup> is the most common activating mutation in melanoma and patients treated with BR...
The recent studies have revealed that most BRAF inhibitors can paradoxically induce kinase activatio...
As a central element within the RAS/ERK pathway, the serine/threonine kinase BRAF plays a key role ...
SummaryTreatment of cancer patients with ATP-competitive inhibitors of BRAF/CRAF kinases surprisingl...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
Treatment of cancer patients with ATP-competitive inhibitors of BRAF/CRAF kinases surprisingly incre...
The EGFR/ErbB/HER family of kinases contains four homologous receptor tyrosine kinases that are impo...
Various BRAF kinase inhibitors were developed to treat cancers carrying the BRAFV600E mutation. Firs...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Using quantitative proteomics we mapped the interactomes of RAF1 monomers, RAF1-BRAF and RAF1-BRAFV6...
Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in kinase-impaired or ...
The RAF/MEK/ERK pathway is central to the control of cell physiology, and its dysregulation is assoc...
The emerging structural information about allosteric kinase complexes and the growing number of allo...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
An autoinhibitory network of hydrogen bonds located at the kinase hinge (referred to as the "molecul...
BRAF<sup>V600E</sup> is the most common activating mutation in melanoma and patients treated with BR...
The recent studies have revealed that most BRAF inhibitors can paradoxically induce kinase activatio...
As a central element within the RAS/ERK pathway, the serine/threonine kinase BRAF plays a key role ...
SummaryTreatment of cancer patients with ATP-competitive inhibitors of BRAF/CRAF kinases surprisingl...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
Treatment of cancer patients with ATP-competitive inhibitors of BRAF/CRAF kinases surprisingly incre...
The EGFR/ErbB/HER family of kinases contains four homologous receptor tyrosine kinases that are impo...
Various BRAF kinase inhibitors were developed to treat cancers carrying the BRAFV600E mutation. Firs...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Using quantitative proteomics we mapped the interactomes of RAF1 monomers, RAF1-BRAF and RAF1-BRAFV6...
Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in kinase-impaired or ...
The RAF/MEK/ERK pathway is central to the control of cell physiology, and its dysregulation is assoc...
The emerging structural information about allosteric kinase complexes and the growing number of allo...
ABSTRACT BRAF is a notable oncoprotein within the MAPK signaling pathway, which is a pathway that se...
An autoinhibitory network of hydrogen bonds located at the kinase hinge (referred to as the "molecul...
BRAF<sup>V600E</sup> is the most common activating mutation in melanoma and patients treated with BR...